Diagnosis and Treatment Status and Medical Burden of Respiratory Syncytial Virus Infection in Children in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

1100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-15

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To understand the diagnosis and treatment status and medical burden of respiratory syncytial virus (RSV) infection in children in China, and to provide scientific basis for formulating prevention and treatment strategies for children. According to the seven administrative regions of China, namely Northeast, North, Northwest, Southwest, Central, South and East China, 1-3 children's medical institutions were selected from each region, and the cases of bronchiolitis or pneumonia admitted to hospitals and diagnosed as RSV positive by etiology during January 1, 2017 to December 31, 2021 were selected. Demographic data and clinical information were collected, and subgroup analysis was designed to explore the relationship between them and medical expenses and clinical treatment burden.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Long-term Effect of RSV Infection

NCT03876249

Asthma in Children

UNKNOWN

Peginterferon α-2b Injection for the Treatment of Pediatric RSV Bronchiolitis

NCT06827249

Bronchiolitis

RECRUITING NA

The Status Quo of Diagnosis and Treatment of Pediatric Outpatients With Respiratory Diseases

NCT04855604

Respiratory Diseases

UNKNOWN

Effectiveness of Nirsevimab in Children Hospitalised With RSV Bronchiolitis

NCT06030505

Bronchiolitis, Viral

COMPLETED

COVID-19 Impact on RSV Emergency Presentations

NCT04959734

Bronchiolitis; Respiratory Syncytial Virus

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

RSV Infection Disease Burden

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

uninvolved

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Hospitalized patients under 18 years of age with an etiological diagnosis of RSV-positive bronchiolitis or pneumonia

Exclusion Criteria

Inpatients under 18 years of age with an etiological diagnosis of RSV-positive bronchiolitis or pneumonia are excluded from any of the following criteria:

1. Pneumonia occurring 48 hours after hospitalization;
2. Combined with bronchial foreign body;
3. Participants in clinical trials of drugs or medical devices;
4. Not complete personal and family history and other relevant information.

Minimum Eligible Age

0 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No